Alger Expands Health Care Team with Two Senior Investment Hires
Alger is pleased to announce that Dr. Sanjiv Talwar and Keye S.K. Chow have joined the firm to expand its health care sector team.
NEW YORK, July 1, 2021 /PRNewswire-PRWeb/ -- Fred Alger Management, LLC ("Alger"), a $45-billion growth equity investment manager, is pleased to announce that Dr. Sanjiv Talwar and Keye S.K. Chow have joined the firm to expand its health care sector team.
Dr. Talwar joined as senior vice president, senior analyst, portfolio manager and head of health care. Mr. Chow joined as senior vice president and senior analyst.
"I am pleased to welcome Sanjiv and Keye to Alger's investment team," said Dan Chung, CEO and Chief Investment Officer. "Sanjiv brings significant health care experience to our organization and I believe his deep knowledge of the sector will be valuable to our firm and our clients. Keye has spent the majority of his career investing in health care and technology and I believe he will be a key contributor given his emphasis on bottom-up, fundamental research."
Sanjiv also joins Dan as a portfolio manager on the four-star Morningstar rated Alger Health Sciences Fund and the Alger Large Cap Growth strategy.
Dr. Talwar has 15 years of investment experience and more than 12 years of experience in scientific and medical research. Before joining Alger, Sanjiv was a portfolio manager for a life sciences fund at Invesco, where he also served as a senior health care analyst on a global fund. Prior to that, he was an associate principal at McKinsey & Company, where he led consulting teams focused on health care, serving industry and private equity globally. Sanjiv's research experience includes roles as a research assistant professor in the Department of Pharmacology and Physiology at the State University of New York and a postdoctoral fellow in the Department of Neuroscience at the University of Pennsylvania, where he helped develop the science of brain-machine interfaces. He was also a resident surgeon in Mumbai, India and a professional squash player in the U.S. Sanjiv earned an M.D. from the University of Bombay and both a Ph.D. and an M.B.A. from the University of Pennsylvania.
Keye has 17 years of investment experience, most recently as a senior equity analyst and sector portfolio manager at Invesco, where he led fundamental research and stock selection across health care services, medical technology and biopharmaceutical companies. Prior to that, Keye was an equity analyst covering health care and technology at several investment managers, including Millennium, Credit Suisse, Ivory Capital Management and Palmyra Capital Advisors. He also gained experience in the technology industry during his time in business development and corporate development roles for Documentum and RSA Security, respectively. Early in his career, he worked as an investment banker at Merrill Lynch and a strategy consultant at LEK Consulting. Keye earned a B.A. in English and an M.S. in Industrial Engineering at Stanford University. He also earned an M.B.A. from Harvard Business School.
About Alger
Founded in 1964, Alger is widely recognized as a pioneer of growth-style investment management. Headquartered in New York City with affiliate offices in Boston and London, Alger provides U.S. and non-U.S. institutional investors and financial advisors access to a suite of growth equity separate accounts, mutual funds, and privately offered investment vehicles. The firm's investment philosophy, discovering companies undergoing Positive Dynamic Change, has been in place for over 50 years. Weatherbie Capital, LLC, a Boston-based investment adviser specializing in small and mid-cap growth equity investing is a wholly-owned subsidiary of Alger. For more information, please visit http://www.alger.com.
Risk Disclosures: Investing in the stock market involves risks, including the potential loss of principal. Growth stocks may be more volatile than other stocks as their prices tend to be higher in relation to their companies' earnings and may be more sensitive to market, political, and economic developments. Local, regional or global events such as war, acts of terrorism, the spread of infectious illness such as COVID-19 or other public health issues, recessions, or other events could have a significant impact on investments. A significant portion of assets will be invested in healthcare companies, which may be significantly affected by competition, innovation, regulation, and product obsolescence, and may be more volatile than the securities of other companies. Investing in companies of small capitalizations involve the risk that such issuers may have limited product lines or financial resources, lack management depth, or have limited liquidity. Private placements are offerings of a company's securities not registered with the SEC and not offered to the public, for which limited information may be available. Such investments are generally considered to be illiquid. Foreign securities involve special risks including currency fluctuations, inefficient trading, political and economic instability, and increased volatility. Active trading may increase transaction costs, brokerage commissions, and taxes, which can lower the return on investment.
This material is not meant to provide investment advice and should not be considered a recommendation to purchase or sell securities.
©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Morningstar calculates a Morningstar Rating ™ based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund's monthly performance, placing more emphasis on downward variations and rewarding consistent performance. The Morningstar Rating may differ among share classes of a mutual fund as a result of different sales loads and/or expense structures. It may be based in part, on the performance of a predecessor fund. The Morningstar Rating does not include any adjustment for sales loads. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. Alger Health Sciences Fund Z was rated 4, 5, and 3 Star(s) for the 3-, 5-, and 10-year periods among 136, 127, and 104 Health funds as of 3/31/21.
Rankings and ratings may be based in part on the performance of a predecessor fund or share class and are calculated by Morningstar using a performance calculation methodology that differs from that used by Fred Alger Management, Inc.'s. Differences in the methodologies may lead to variances in calculating total performance returns, in some cases this variance may be significant, thereby potentially affecting the rating/ranking of the Fund(s). When an expense waiver is in effect, it may have a material effect on the total return or yield, and therefore the rating/ranking for the period.
Before investing, carefully consider a Fund's investment objective, risks, charges, and expenses. For a prospectus and summary prospectus containing this and other information or for a Fund's most recent month-end performance data, visit http://www.alger.com, call (800) 992-3863 or consult your financial advisor. Read the prospectus and summary prospectus carefully before investing.
Distributor: Fred Alger & Company, LLC. NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE.
Media Contact
Scott Anderson, Alger, 212-806-2972, [email protected]
Sheila Kulik, Prosek, 203-745-2523, [email protected]
SOURCE Alger
Share this article